Johnson & Johnson beefs up its surgery robotics tech with acquisition of French company

surgical robotics
Johnson & Johnson is beefing up its presence in the robotic surgery arena with the acquisition of French robot-assisted surgery company Orthotaxy. (Shutterstock)

Johnson & Johnson is beefing up its presence in the robotic surgery arena with the acquisition by its unit Apsis of French robot-assisted surgery company Orthotaxy for an undisclosed price.

The company said the deal for Orthotaxy is part of its strategy to create a new robot-assisted platform for orthopedic surgeries beyond its current early stage technology focused on total and partial knee replacements.

“Our goal is to bring to market a robotic-assisted surgery technology that is an integral part of a comprehensive orthopedics platform,” Ciro Rӧmer, chairman of J&J’s DePuy Synthes orthopedics business, said in a statement. “The team at Orthotaxy has significant expertise and passion in developing this platform, and we aspire to bring to market a differentiated technology that helps improve clinical outcomes and increases patient satisfaction.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Orthotaxy was founded by Stéphane Lavallée, a robotics entrepreneur.

J&J is also part of a robotics joint venture with Verb Surgical, which a little over a year ago unveiled its first digital surgery prototype to its partners. At the time of the announcement, Verb said the prototype met all of the companies' “technology pillars,” including robotics, visualization, advanced instrumentation, data analytics and connectivity.

Suggested Articles

Flatiron has hired a new chief medical officer as it looks to push on under its new parent in the world of electronic health records and real-world data.

Saga Diagnostics has raised 40 million Swedish kronor, or about $4.1 million, to help develop its ultrasensitive cancer liquid biopsy tests.

Terumo will help Orchestra BioMed develop its sirolimus-eluting balloon in both coronary and peripheral cardiovascular interventions.